FDAnews
www.fdanews.com/articles/96644-gtc-biotherapeutics-and-lfb-biotechnologies-developing-cd20-antibody

GTC Biotherapeutics and LFB Biotechnologies Developing CD20 Antibody

August 2, 2007

GTC Biotherapeutics, Inc. and LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire francais du Fractionnement et des Biotechnologies S.A.), announced that they have initiated development of a transgenically produced CD20 monoclonal antibody under the existing agreement between GTC and LFB Biotechnologies.
GTC Biotherapeutics